Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beyond Air, Inc.XAIR · Entity 8379 | Director · Chief Executive Officer | July 29, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beyond Air, Inc.
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,822 |
Reported balance
After 2026-07-29 transaction · row 1
1 source rowRow 1 · 2026-07-29 · Purchase · Acquired 34,722 · Balance 34,822 |
| Series A WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.51 | Direct | 34,722 |
Reported balance
After 2026-07-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-29 · Purchase · Acquired 34,722 · Balance 34,722 F3: Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76. F1: Exercisable immediately upon issuance F2: Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II |
| Series B WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.51 | Direct | 34,722 |
Reported balance
After 2026-07-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-29 · Purchase · Acquired 34,722 · Balance 34,722 F3: Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76. F1: Exercisable immediately upon issuance F4: 5 years following date of issuance |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable immediately upon issuance
F2: Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II
F3: Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76.
F4: 5 years following date of issuance
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 31, 2026 22:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseSeries B Warrants · Derivative | 34,722 | Not disclosed Strike: $5.51 | Not disclosed |
DisclosureSEC source: 0001493152-26-035702 · ownership.xml · derivative · entry 3 Goodman Robert Scott · CIK 0002075668 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,722 Underlying: Common Stock · 34,722 shares Expires not disclosed F3 · price: Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76. F1 · derivative.exercise_date: Exercisable immediately upon issuance F4 · derivative.expiration_date: 5 years following date of issuance Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 22:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseSeries A Warrants · Derivative | 34,722 | Not disclosed Strike: $5.51 | Not disclosed |
DisclosureSEC source: 0001493152-26-035702 · ownership.xml · derivative · entry 2 Goodman Robert Scott · CIK 0002075668 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,722 Underlying: Common Stock · 34,722 shares Expires not disclosed F3 · price: Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76. F1 · derivative.exercise_date: Exercisable immediately upon issuance F2 · derivative.expiration_date: Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 22:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 34,722 | $5.76 | $199,998.72 |
DisclosureSEC source: 0001493152-26-035702 · ownership.xml · nonDerivative · entry 1 Goodman Robert Scott · CIK 0002075668 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,822 Read SEC document |
| November 04, 2025 Filed Nov 7, 2025 02:48 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 187 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001493152-25-021148 · ownership.xml · derivative · entry 4 Goodman Robert Scott · CIK 0002075668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187 Underlying: Common Stock · 187 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 04, 2025 Filed Nov 7, 2025 02:48 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 187 | Not disclosed Strike: $10.80 | Not disclosed |
DisclosureSEC source: 0001493152-25-021148 · ownership.xml · derivative · entry 3 Goodman Robert Scott · CIK 0002075668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 04, 2025 Filed Nov 7, 2025 02:48 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 187 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001493152-25-021148 · ownership.xml · derivative · entry 2 Goodman Robert Scott · CIK 0002075668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187 Underlying: Common Stock · 187 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 04, 2025 Filed Nov 7, 2025 02:48 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 187 | Not disclosed Strike: $10.80 | Not disclosed |
DisclosureSEC source: 0001493152-25-021148 · ownership.xml · derivative · entry 1 Goodman Robert Scott · CIK 0002075668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187 shares Expires not disclosed F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F1 · price: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 21:57 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 3,750 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001641172-25-024676 · ownership.xml · derivative · entry 1 Goodman Robert Scott · CIK 0002075668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 3,750 shares Expires 2035-08-14 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2025, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. F2 · balance_after: Includes additional 2,000 stock split adjusted shares of common stock held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.